Business ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials GLP-1 Drugs Weight Loss Drugs Acquisitions Eli Lilly Oncology Obesity Drugs Obesity Treatments Eli Lilly and Company Market Performance

Eli Lilly Tops GLP‑1 Market as Sales Soar

Strong first-quarter growth from tirzepatide and Mounjaro pushed the company’s valuation higher, with dividend yield remaining about 0.6%.

Pfizer CFO Dave Denton to Exit and Cecile Guegan Named Interim

Eli Lilly Spends $3.8 Billion to Build Vaccine Business

Bristol Myers and Pfizer Offer Big Yields but Face Patent and Payout Risks

Servier to Buy Edgewise Muscular Dystrophy Unit for Up to $2.65 Billion

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Bristol Myers Squibb to Deploy Anthropic’s Claude Across Global Operations

PolyPid Nears Completion of Rolling FDA Filing for D‑PLEX100

Merck KGaA Raises 2026 Profit Outlook After Q1 Beat

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion to Bolster Eye Pipeline

ADC Therapeutics Reports Higher Q1 Sales and Lower Costs as Zenlonta Readouts Near

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

AbbVie Tops Q1 and Raises 2026 Outlook as Skyrizi and Rinvoq Offset Humira Decline

Sun Pharma Said to Make $13 Billion All-Cash Offer for Organon

Cramer Touts Intel Comeback Under Lip‑Bu Tan as Earnings Loom

Novo Nordisk Partners With OpenAI to Speed Drug Development and Operations

Boehringer Ingelheim Transfers CT-155 Commercial Rights to Click Therapeutics With $50 Million Backing